Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027121 (
myositis
)
4,538
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The purpose of this case report is to document the treatment of a patient who had traumatic
myositis
ossificans with
acetic acid
iontophoresis. A 16-year-old boy developed quadriceps femoris muscle
myositis
ossificans as a result of a springboard diving accident. A 2%
acetic acid
solution was administered via iontophoresis into the
myositis
ossificans, followed by 8 minutes of pulsed ultrasound at 1.5 W/cm2. The treatment was performed three times per week for 3 weeks. At the conclusion of the treatments, radiographic findings indicated a 98.9% decrease in the size of the ossified mass. The patient regained full range of motion and was able to return to pain-free activity. This case report demonstrates the potential for a therapeutic program of
acetic acid
iontophoresis and ultrasound in eliminating
myositis
ossificans.
...
PMID:Treatment of traumatic myositis ossificans with acetic acid iontophoresis. 154 34
This case report describes the occurrence of bilateral
myositis
ossificans in the rectus femoris muscles of a young Gaelic football player with a long history of recurrent bilateral thigh strain. In each case, clinical diagnosis was followed up with biochemical profiling and sonographic investigations. Management consisted of rest from elite level competition and intense rehabilitation to address any potential risk factors for rectus femoris strain. A 4-week course of
acetic acid
iontophoresis was administered to the first
myositis
ossificans lesion on the left thigh; however, as this did not result in any significant changes to the lesion's dimensions, it was not used on the contralateral lesion. The athlete returned to full sporting capacity 4 months after the first lesion was diagnosed. A 13-month follow-up showed that the athlete continued to play to full capacity with no recurrence of injury.
...
PMID:An unusual case of bilateral myositis ossificans in a young athlete. 2169 98
The chemokine fractalkine (CX3C chemokine ligand 1; CX3CL1) and its receptor CX3CR1 are involved in the pathogenesis of several diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, rheumatoid arthritis, hepatitis,
myositis
, multiple sclerosis, renal ischemia, and atherosclerosis. There are no orally available agents that modulate the fractalkine/CX3CR1 axis. [(3
S
,4
R
)-1-[2-Chloro-6-(trifluoromethyl)benzyl]-3-{[1-(cyclohex-1-en-1-ylmethyl)piperidin-4-yl]carbamoyl}-4-methylpyrrolidin-3-yl]
acetic acid
(2S)-hydroxy(phenyl)acetate (E6130) is an orally available highly selective modulator of CX3CR1 that may be effective for treatment of inflammatory bowel disease. We found that E6130 inhibited the fractalkine-induced chemotaxis of human peripheral blood natural killer cells (IC
50
4.9 nM), most likely via E6130-induced down-regulation of CX3CR1 on the cell surface. E6130 had agonistic activity via CX3CR1 with respect to guanosine 5'-3-
O
-(thio)triphosphate binding in CX3CR1-expressing Chinese hamster ovary K1 (CHO-K1) membrane and had no antagonistic activity. Orally administered E6130 ameliorated several inflammatory bowel disease-related parameters in a murine CD4
+
CD45RB
high
T-cell-transfer colitis model and a murine oxazolone-induced colitis model. In the CD4
+
CD45RB
high
T-cell transfer model, E6130 inhibited the migration of CX3CR1
+
immune cells and decreased the number of these cells in the gut mucosal membrane. These results suggest that E6130 is a promising therapeutic agent for treatment of inflammatory bowel disease.
...
PMID:E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1
+
Leukocyte Trafficking in Mice with Colitis. 2884 93
